home / stock / dice / dice quote
Last: | $47.55 |
---|---|
Change Percent: | -0.08% |
Open: | $47.59 |
Close: | $47.55 |
High: | $47.8301 |
Low: | $47.46 |
Volume: | 4,332,950 |
Last Trade Date Time: | 08/08/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$47.55 | $47.59 | $47.55 | $47.8301 | $47.46 | 4,332,950 | 08-08-2023 |
$47.52 | $47.45 | $47.52 | $47.67 | $47.4 | 1,823,647 | 08-07-2023 |
$47.31 | $47.55 | $47.31 | $47.6 | $47.19 | 1,104,218 | 08-04-2023 |
$47.45 | $47.52 | $47.45 | $47.52 | $47.4 | 1,408,802 | 08-03-2023 |
$47.38 | $47.11 | $47.38 | $47.9 | $47.08 | 2,922,048 | 08-02-2023 |
$47.21 | $47 | $47.21 | $47.25 | $47 | 817,758 | 08-01-2023 |
$47 | $46.98 | $47 | $47.02 | $46.9 | 544,354 | 07-31-2023 |
$46.99 | $47.03 | $46.99 | $47.03 | $46.95 | 630,918 | 07-28-2023 |
$46.95 | $47 | $46.95 | $47.11 | $46.93 | 610,627 | 07-27-2023 |
$46.95 | $46.9 | $46.95 | $47.025 | $46.81 | 457,446 | 07-26-2023 |
$46.87 | $46.87 | $46.87 | $46.94 | $46.81 | 1,252,661 | 07-25-2023 |
$46.97 | $46.68 | $46.97 | $47.01 | $46.66 | 958,571 | 07-24-2023 |
$46.65 | $46.8 | $46.65 | $46.89 | $46.635 | 1,189,003 | 07-21-2023 |
$46.77 | $46.84 | $46.77 | $46.89 | $46.7 | 884,584 | 07-20-2023 |
$46.8 | $46.94 | $46.8 | $47.1 | $46.8 | 994,215 | 07-19-2023 |
$46.85 | $46.71 | $46.85 | $46.87 | $46.71 | 859,557 | 07-18-2023 |
$46.73 | $46.64 | $46.73 | $46.78 | $46.62 | 892,120 | 07-17-2023 |
$46.62 | $46.65 | $46.62 | $46.75 | $46.58 | 1,071,414 | 07-14-2023 |
$46.63 | $46.72 | $46.63 | $46.78 | $46.56 | 1,551,084 | 07-13-2023 |
$46.7 | $46.92 | $46.7 | $46.95 | $46.64 | 2,122,026 | 07-12-2023 |
News, Short Squeeze, Breakout and More Instantly...
DICE Therapeutics Inc. Company Name:
DICE Stock Symbol:
NASDAQ Market:
DICE Therapeutics Inc. Website:
BiondVax (NASDAQ: BVXV) , a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently recei...
Lilly Completes Acquisition of DICE Therapeutics PR Newswire INDIANAPOLIS , Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition...
BiondVax, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, was featured in a recent analyst report reiterating a Buy recommendation and a $70 target price The report discussed Eli Lilly’s announcement of a definitive...